Latest news
Prevention Is Now Alzheimer’s Hardest Trial
Roche’s PrevenTRON trial moves trontinemab into cognitively unimpaired people at high biological risk of Alzheimer’s decline. The science is bold. The ethics and access questions are even bigger.
Ebola May Be Reaching Kisangani. Containment Cannot Stay Provincial.
New global heart failure definition exposes a policy gap: systems still diagnose too late and treat too narrowly
Sugar substitutes were sold as metabolic shortcuts. The evidence is getting harder to ignore
Early Lung Cancer Just Became a Biomarker Test of the System
Pancreatic Cancer’s ADC Moment Will Live or Die by the Biomarker
Duchenne Evidence Moves Into the Muscle
Moldova Is Taking Vaccines To Roma Communities. Respect Is Part Of Delivery.
Merck KGaA’s Saturnus Bio bet signals a shift to genotype-driven cardiology, and a looming readiness gap for health systems
Same country, different risks: why Iranian women’s heart disease profiles expose a blind spot in prevention policy
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.